Wake Research Associates, LLC

Wake Research Associates, LLC is a clinical research organization specializing in conducting clinical trials and research studies to enhance medical knowledge and healthcare outcomes across North America. Established in 1984 and headquartered in Raleigh, North Carolina, Wake Research Associates, LLC focuses on clinical trials, collaborating with biopharmaceutical and medical device companies. The organization was acquired by M3, Inc. from Gemini Investors and Timepiece Capital in February 2018.

Ella Grach currently serves as the CEO of the company. M3 Wake Research specializes in conducting clinical trials and research studies aimed at advancing medical knowledge and improving healthcare outcomes. The organization operates a network of premier investigational sites across North America, collaborating with biopharmaceutical, biotechnology, and medical device companies, as well as clinical research organizations. Their core offerings encompass the recruitment, qualification, and retention of volunteers for a diverse array of trials, including experimental drug studies and cancer research.

These services cater primarily to patients, caregivers, and healthcare providers, ensuring that clinical trials are accessible to a broad population. M3 Wake Research serves a wide geographical market, with its clinical trials implemented throughout the United States, focusing on various conditions and therapies. The revenue model of M3 Wake Research revolves around partnerships and contracts with biopharmaceutical and medical research companies seeking to conduct clinical trials. Transactions typically occur on a contractual basis, where sponsors fund the trials based on the services provided, including recruitment and data collection.

Revenue is generated through fee structures established for each study, which may involve one-time payments or ongoing fees depending on the duration and complexity of the trials. The organization emphasizes the importance of ethical practices and maintains the integrity of clinical data throughout the research process. While specific pricing details regarding their services are not disclosed, M3 Wake Research's offerings are integral to the advancement of healthcare, helping to expedite the development of new therapies and medical devices. Following the acquisition by M3, Inc.

, M3 Wake Research plans to leverage its enhanced capabilities to expand its network of investigational sites and increase the scope of clinical trials. The company is targeting new markets across North America to enhance its operational reach by 2023. The funding from the acquisition deal in February 2018 will support these initiatives, allowing M3 Wake Research to further develop its services and foster partnerships within the biopharmaceutical industry.